CCM
RARX

Consonance Capital Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Consonance Capital Management’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,454,761
Closed -$26.3M – 31
2018
Q3 		$26.3M Hold
1,454,761
– – 1.42% 24
2018
Q2 		$14.5M Hold
1,454,761
– – 0.93% 26
2018
Q1 		$7.72M Buy
+1,454,761
New +$10.4M 0.71% 24

Other funds holding RARX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MMPI
Morgenthaler Management Partners IX Portola Valley, California $22.6M AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Consonance Capital Management's RARX Position: Q4 2018 in Review

Consonance Capital Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q4 2018, closing a stake of 1,454,761 shares — an estimated $26.3M sold.

Consonance Capital Management first reported a position in RARX in Q1 2018 and held it in 3 quarters. The position peaked at $26.3M in Q3 2018. 94 funds tracked by Wall St. Rank hold RARX as of Q4 2018.

  • Consonance Capital Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Consonance Capital Management sold 1,454,761 Ra Pharmaceuticals, Inc. Common Stock shares in Q4 2018, an estimated $26.3M.
  • Consonance Capital Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q1 2018 and held it in 3 quarters.
  • Consonance Capital Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $26.3M in Q3 2018.
  • 94 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q4 2018.

Based on Consonance Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.